Attend
Read
Watch
Listen
About Us
Stay Informed.
Sign-up for the SynBioBeta Weekly Digest and stay on top of all the industry news.
Thank you!
We'd love to ask a few more questions to better customize your experience.
Oops! Something went wrong while submitting the form.
Thank You!
We'd love to get to know you just a bit more.
Take a few minutes to personalize your content.
What is the size of your company?
Synbio Stack?
Synbio Stack?
BACK
NEXT
Thank you!
You are now subscribed.
Oops! Something went wrong while submitting the form.
Weekly Digest

bit.bio

https://bit.bio
How is 
bit.bio
 using biology to make the world a better place?

bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines. This is possible with our next generation cell programming technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.

A little more about 
bit.bio

We are entering the new era of regenerative medicine, an era in which our repertoire of molecular drugs will be expanded to living medicines. Cell transplants will replace faulty cells to cure chronic and deadly diseases. Where today’s small molecules and biologics struggle, cells can make a difference. The revolutionary impact of cell therapies has already become apparent: engineered CAR-T-cells are able to cure blood cancers that used to be untreatable. The application of one single cell type gave rise to the first wave of cell therapy companies. This is the beginning of a new industry that will harness the regenerative power of many more cells in the human body. Several bottlenecks remain - access to a reliable, consistent supply of cells that are highly defined and precisely match the needs of the patient and the disease. At the moment / today, cell therapies rely on donors or patients. Manufacturing cells at scale, with consistency, and precision is challenging; as a consequence, today’s treatments are bespoke and costly. To solve these hurdles and to make cell therapies accessible for all patients, a revolution in how cells are manufactured is needed. What if a company had the power to create every human cell type, without the need of harvesting cells from a donor? If it were able to manufacture human cells with the consistency and quality suitable for a medicine? - Every single cell type has the potential to give rise to multiple next generation therapies, and possibly entire industries. To unlock this new generation of therapies, bit.bio is developing the foundational technology to manufacture human cells at scale, with unmatched precision and consistency. A new paradigm in biology makes this possible: coding cells with a new identity. bit.bio’s software-like approach to biology is based on our ability to read, write, and execute genetic code in human cells. This approach allows robust manufacturing of cells that are defined at a sub-cell identity, for example a microglia versus a macrophage, and we can even code the maturity level of a cell. bit.bio serves two markets: R&D and clinical therapy. R&D cell products - bit.bio’s developer’s tool kit: ioCell products enable researchers in academia and industry to innovate and super-charge drug development by enabling high throughput screening. Our rapidly expanding ioCell portfolio includes product lines consisting of glutamatergic neurons and myocytes that are validated as best in class human cells by KoLs and leading industry partners. Cell therapy applications: the knowledge and validation gained in the R&D market and our growing pipeline of cells will fuel the development of clinical cell therapies. Every cell we create is a new potential app for us or partners to create the next generation of medicines.